NDATOPICALCREAM
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UTICORT (betamethasone benzoate) is a potent topical corticosteroid cream approved in 1974 for inflammatory and pruritic dermatological conditions. It works by suppressing the immune response and reducing inflammation at the skin surface. The drug is indicated for conditions such as eczema, psoriasis, and other steroid-responsive dermatoses.
LOE Approaching
With LOE approaching and limited linked job activity, the brand team is likely in maintenance mode with minimal expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on UTICORT offers limited career advancement given its LOE trajectory and minimal linked job openings. Roles on this product are typically maintenance-focused rather than growth-oriented, making it a challenging assignment for career development.
Brand ManagerField Sales Representative
Worked on UTICORT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.